Sabby Management, LLC Inhibikase Therapeutics, Inc. Transaction History

Sabby Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $1.44 $62,370 - $142,560	-99,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.03 - $1.77 $335,794 - $577,044	-326,014 Reduced 76.71%	99,000 $147,000
Q3 2021 Nov 15, 2021	BUY	$1.79 - $2.81 $6,827 - $10,717	3,814 Added 0.91%	425,014 $808,000
Q2 2021 Aug 16, 2021	BUY	$2.8 - $6.23 $1.18 Million - $2.62 Million	421,200 New	421,200 $1.18 Million

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $75.4M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.